Curewize is a leader in the field of personalized medicine, diagnostics and predictive medicine. The Company's goal is to improve the survival rate and overall health outcome of cancer patients. Our proprietary platform technology measures microRNA (miRNA) profiles in patients’ biofluids. MiRNAs control gene activity, and are considered superior biomarkers for diagnosis and personalized treatment decisions due to their direct link to cancer mechanisms and stability in human biofluid samples. The company’s initial product is ProALL, a groundbreaking lab test for deciding on the intensity of treatment of acute lymphoblastic leukemia (ALL) patients. Lead Product The ProALL bone marrow (BM) lab test is our lead product, measuring the level of three miRNA molecules in samples taken a...Read More
Curewize is positioned with an accurate, industrial standard proprietary platform technology. Our mangement are experts in the development and commercRead More
Translate and transfer microRNA biomaker lab tests to clincial practice. Connecting groundbreaking academic discoveries to Curewize platform technolgyRead More
Personalized medicine seperates cancer patients into different groups for precise treatment decisions and tailored medicine. Personalized medicine isRead More
Create tools based on microRNA biomarkers for tailoring cancer patients optimal treatment. Curewize is industrializing cancer-specific prognostiRead More
Date : 28.05.2018
Curewize is proud to be presenting results at the 23rd EHA congress in Sweden, June 16 2018: 1. ProALLBM clinical trial on AIEOP B-ALL cohort and 2. miR-451 tumor suppresor study.
Date : 03.04.2018
Curewize successfully completed the clinical trial of its lead product ProALLBM on a cohort of acute lymphoblastic leukemia (ALL) patients from a European National Registry Study. ProALLBM is being produced for deciding on ALL patients risk-based treatment group, varying from standard to i ...
Date : 24.01.2017
Curewize Health Ltd., a diagnostic company focused on the development of proprietary diagnostics for the treatment of Acute Lymphoblastic Leukemia (ALL), announced that the Israeli Patent Authority has indicated on January 24, 2017 that it intends to grant a patent relating to Curewize’s ProAL ...